Skip to main content
Equibles
AKTX logo

AKTX · Akari Therapeutics Plc · Metrics

Track AKTX — free

Use AKTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AKTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.76 -0.53 (-5.71%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the "consolidated financial statements") are issued.”
View the 10-Q filed Aug 13, 2026
Market Cap
$22.14M
Shares
2.29M
Volume · Oct 21 30.6K Avg daily vol (3M) 60.83K

AKTX metrics

54 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.76
Market cap
$22.14M

Price action

20 metrics
Price change (1W)
+17.6%
Price change (30D)
-1.0%
Price change (3M)
-0.1%
Price change (6M)
+58.3%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
380.8%
Annualized volatility (3M)
111.2%
Beta
1.5
RSI (14D)
51.7
Price vs SMA 50
+1.4%
Price vs SMA 200
—
Avg volume (3M)
61,437
Relative volume
0.6
Average dollar volume
$573,961

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
52.2×
reciprocal yield 1.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
62.3×
reciprocal yield 1.6%
P / book
1.2
reciprocal yield 84.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-140.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-4,568.4%
Trailing 12 months
Net margin
-2,720.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$30.99M
Net income (TTM)
−$30.96M
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-39.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$354,023
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+127.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-166.5%
Return on assets
-80.2%
Debt / equity
—
Current ratio
0.6
EBITDA (TTM)
−$21.63M
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
-227.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$7.69M
Total assets
$38.62M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.76M
Capital expenditures (TTM)
—
R&D (TTM)
$4.87M
SG&A (TTM)
$8.81M
Stock compensation (TTM)
$2.17M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
10
13F filer change QoQ
+4
Institutional ownership
7.0%
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+124.1%
Holder tenure
2.1
Price vs estimated holder cost
+35.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.6%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
41 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1541157 CUSIP 00972G405 13F (30d) 2 filings 2 filers Visit website Investor relations